news
Remynd strenghtens drug development focus with strategic sale of CRO business to InnoSer
04/03/2025, Leuven, Belgium – Leuven biotech player remynd announces its strategic transition into an organization purely focused on drug development. Remynd will concentrate on developing its proprietary small molecule programs for the treatment of neurodegenerative disease, while the company’s contract research organization (CRO) business unit will be fully integrated within InnoSer. The strategic sale ensures that remynd’s deep expertise in preclinical models of neurodegeneration remains available to the global pharma and biotech community.
Remynd started in a dual-focus business model where the service arm supported its early drug discovery activities. This model has enabled remynd to identify novel mechanisms-of-action, innovative targets, and proprietary small molecules showing high potency and efficacy.
Its lead program REM392 represents a novel approach to treat Alzheimer's disease and is expected to provide both alleviation of symptoms and modification of underlying disease processes. A first-in-human study is scheduled to start later this year. The company’s Huntington’s disease program is ready to enter CTA-enabling studies.
Going forward, remynd’s CRO business unit will operate within InnoSer, a dedicated preclinical service provider, allowing remynd to focus exclusively on progressing its (pre)clinical programs.
"For remynd, the divestment from our CRO unit is a logical next step in our evolution into a clinical-stage company," says CEO Floor Stam. "At the same time, we are pleased that our CRO unit will continue to serve its global partners, a mix of big pharma players and a wide range of biotechs, under the InnoSer name."
Johan Cardoen, Chairman of remynd: "This transition marks an important milestone for remynd. This full commitment to drug development will drive value creation and turn our pioneering programs into solutions that patients and caregivers are desperately waiting for.”
Kris Motmans, InnoSer CEO adds: "Remynd has built a strong reputation for developing rigorous, highly translational neurodegenerative models. We are proud to integrate these into InnoSer’s neurology platform, ensuring their continued availability to the preclinical research community. This acquisition strengthens our position as a leading European CRO and enhances our ability to provide high-quality preclinical solutions for neurodegenerative research."
In the next months, remynd and InnoSer will work together intensively to ensure a seamless transition of all CRO operations.
